Increasing the remission rate and reducing the recurrence rate can improve the clinical
efficacy of chimeric antigen receptor (CAR) T cell therapy in recurrent/refractory non …

Two autologous anti‐CD19 chimeric antigen receptors (CAR) T cells (axicabtagene
ciloleucel [axi‐cel] and tisagenlecleucel [tisa‐cel]) are commercially approved in Europe for …

The prognosis of patients with large B-cell lymphoma (LBCL) that progresses after treatment
with chimeric antigen receptor (CAR) T-cell therapy targeting CD19 (CAR19) is poor. We …

Relapsed or refractory aggressive B-cell lymphoma has an extremely poor prognosis and
efforts to develop novel therapies for these patients have failed for almost four decades until …

Chimeric antigen receptor (CAR) T-cell therapies that target either CD19 or CD22 alone
have potent antilymphoma effects. However, antigen escape–mediated relapse often …

Abstract Axicabtagene ciloleucel (YESCARTA; Kite Pharma, a Gilead Company, Los
Angeles CA) and tisagenlecleucel (KYMRIAH; Novartis Pharmaceuticals Corp., Basel …

Patients with relapsed or refractory non-Hodgkin lymphoma have a dismal prognosis.
Chimeric Antigen Receptor (CAR)-modified T cells (CART cells) that targeted CD20 were …

Summary CD19 CAR‐T have emerged as a new standard treatment for relapsed/refractory
(r/r) large B‐cell lymphoma (LBCL). CAR‐T real‐world (RW) outcomes published to date …

Anti-CD19 chimeric antigen receptor (CAR) T-cells represent a major advance in the
treatment of relapsed/refractory aggressive B-cell lymphomas. However, a significant …

Factors associated with durable remission after CD19 chimeric antigen receptor (CAR)-
modified T-cell immunotherapy for aggressive B-cell non-Hodgkin lymphoma (NHL) have …